search
Back to results

Study Comparing G-CSF Mobilized Peripheral Blood and G-CSF Stimulated Bone Marrow in Patients Undergoing Matched Sibling Transplantation

Primary Purpose

Transplantation for Hematologic Malignancies

Status
Completed
Phase
Phase 3
Locations
Saudi Arabia
Study Type
Interventional
Intervention
G-PB Transplant
G-BM Transplant
Sponsored by
King Faisal Specialist Hospital & Research Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Transplantation for Hematologic Malignancies

Eligibility Criteria

16 Years - 65 Years (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Recipient must

    1. Be between the ages of 16 and 65 years old
    2. Have one of the following hematologic malignancies:

      • Acute myeloid leukemia (de novo, secondary or therapy related) in untreated 1st relapse or in remission or with evidence of molecular relapse but blasts less than 5%
      • Chronic myeloid leukemia in chronic or accelerated phase (de novo or therapy related)
      • Myelodysplasia (de novo or therapy related)
      • Other hematologic malignancy (de novo or therapy related) including but not limited to: ALL (CR 1, CR2 or CR3), CLL, non-Hodgkin's lymphoma, Hodgkin's lymphoma
    3. Must be receiving a myeloablative conditioning regimen of busulfan and cyclophosphamide or TBI and cyclophosphamide or other myeloablative regimen approved by the Clinical Study Chair. (Regimens containing ATG are not allowed.)
    4. Have an HLA-identical sibling donor
    5. Meet the transplant centre's criteria for myeloablative allogeneic transplantation*
    6. Have an ECOG performance status of 0, 1 or 2
    7. Have given signed informed consent

Donor must

  1. Be 18 years of age or older. (Upper age limit is at the discretion of the transplant physician at the collection centre.)
  2. Be able to undergo general anesthesia and BM harvest or peripheral blood collection as per assessment by a transplant physician. (If an anesthetist assesses a donor after randomization and determines the donor should not undergo general anesthesia, then the donor and recipient will be withdrawn from the study.)
  3. Be a sibling of the recipient
  4. Be a 6/6 HLA match of the recipient. HLA typing is by serologic or DNA methodology for A and B and by DNA methodology for A and B and by DNA methodology for DRB1 (intermediate resolution)
  5. Have given signed informed consent

Exclusion Criteria

Recipient

1. The recipient is HIV antibody positive

Donor

  1. The donor is unable to undergo general anesthesia, bone marrow harvest or peripheral blood collection
  2. The donor is pregnant or breastfeeding at the time of progenitor cell collection
  3. The donor has a history of malignant disease within the last 5 years or current malignancy other than non-melanomatous in situ skin carcinoma or cervical carcinoma in situ
  4. The donor is HIV antibody positive
  5. The donor has a known sensitivity to E. coli-derived products
  6. The donor and recipient are identical twins

Sites / Locations

  • King Faisal Specialist Hospital & Research Center

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Other

Arm Label

G-BM Transplant

G-PB Transplant

Arm Description

G-PB Transplant

Outcomes

Primary Outcome Measures

Efficacy
The use of G-BM is associated with a longer time to treatment failure (extensive chronic GVHD, relapse, death) than is the use of G-PB for adult myeloablative allogeneic transplantation for hematologic malignancies.

Secondary Outcome Measures

Full Information

First Posted
January 23, 2012
Last Updated
August 9, 2018
Sponsor
King Faisal Specialist Hospital & Research Center
search

1. Study Identification

Unique Protocol Identification Number
NCT01530581
Brief Title
Study Comparing G-CSF Mobilized Peripheral Blood and G-CSF Stimulated Bone Marrow in Patients Undergoing Matched Sibling Transplantation
Official Title
A Randomized Multicentre Study Comparing G-CSF Mobilized Peripheral Blood and G-CSF Stimulated Bone Marrow in Patients Undergoing Matched Sibling Transplantation for Hematologic Malignancies
Study Type
Interventional

2. Study Status

Record Verification Date
August 2018
Overall Recruitment Status
Completed
Study Start Date
November 2008 (undefined)
Primary Completion Date
June 2012 (Actual)
Study Completion Date
June 2014 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
King Faisal Specialist Hospital & Research Center

4. Oversight

5. Study Description

Brief Summary
This is a Randomized Multicentre study Comparing GCSF Mobilized Peripheral Blood and GCSF stimulated Bone Marrow in Patients undergoing matched sibling Transplantation for Haematologic Malignancies.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Transplantation for Hematologic Malignancies

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
230 (Actual)

8. Arms, Groups, and Interventions

Arm Title
G-BM Transplant
Arm Type
Experimental
Arm Title
G-PB Transplant
Arm Type
Other
Arm Description
G-PB Transplant
Intervention Type
Procedure
Intervention Name(s)
G-PB Transplant
Intervention Description
G-PB Transplant
Intervention Type
Procedure
Intervention Name(s)
G-BM Transplant
Intervention Description
G-BM Transplant
Primary Outcome Measure Information:
Title
Efficacy
Description
The use of G-BM is associated with a longer time to treatment failure (extensive chronic GVHD, relapse, death) than is the use of G-PB for adult myeloablative allogeneic transplantation for hematologic malignancies.
Time Frame
2 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
16 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Recipient must Be between the ages of 16 and 65 years old Have one of the following hematologic malignancies: Acute myeloid leukemia (de novo, secondary or therapy related) in untreated 1st relapse or in remission or with evidence of molecular relapse but blasts less than 5% Chronic myeloid leukemia in chronic or accelerated phase (de novo or therapy related) Myelodysplasia (de novo or therapy related) Other hematologic malignancy (de novo or therapy related) including but not limited to: ALL (CR 1, CR2 or CR3), CLL, non-Hodgkin's lymphoma, Hodgkin's lymphoma Must be receiving a myeloablative conditioning regimen of busulfan and cyclophosphamide or TBI and cyclophosphamide or other myeloablative regimen approved by the Clinical Study Chair. (Regimens containing ATG are not allowed.) Have an HLA-identical sibling donor Meet the transplant centre's criteria for myeloablative allogeneic transplantation* Have an ECOG performance status of 0, 1 or 2 Have given signed informed consent Donor must Be 18 years of age or older. (Upper age limit is at the discretion of the transplant physician at the collection centre.) Be able to undergo general anesthesia and BM harvest or peripheral blood collection as per assessment by a transplant physician. (If an anesthetist assesses a donor after randomization and determines the donor should not undergo general anesthesia, then the donor and recipient will be withdrawn from the study.) Be a sibling of the recipient Be a 6/6 HLA match of the recipient. HLA typing is by serologic or DNA methodology for A and B and by DNA methodology for A and B and by DNA methodology for DRB1 (intermediate resolution) Have given signed informed consent Exclusion Criteria Recipient 1. The recipient is HIV antibody positive Donor The donor is unable to undergo general anesthesia, bone marrow harvest or peripheral blood collection The donor is pregnant or breastfeeding at the time of progenitor cell collection The donor has a history of malignant disease within the last 5 years or current malignancy other than non-melanomatous in situ skin carcinoma or cervical carcinoma in situ The donor is HIV antibody positive The donor has a known sensitivity to E. coli-derived products The donor and recipient are identical twins
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Mahmoud Al Jurf, MD
Organizational Affiliation
King Faisal Specialist Hospital & Research Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
King Faisal Specialist Hospital & Research Center
City
Riyadh
ZIP/Postal Code
11211
Country
Saudi Arabia

12. IPD Sharing Statement

Learn more about this trial

Study Comparing G-CSF Mobilized Peripheral Blood and G-CSF Stimulated Bone Marrow in Patients Undergoing Matched Sibling Transplantation

We'll reach out to this number within 24 hrs